Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1861 participants.

Also called NCT05540223

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,861 participants (enrolled count) (from the registry)
Sponsor
  • Biotronik AG Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05540223
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05540223. Randomized; no masking; primary purpose treatment. Start 2024-05-13 (actual); primary completion 2027-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System
Acronym
BIOMAG-II
Condition
Atherosclerosis, Coronary
Condition
Myocardial Ischemia
Condition
Ischemic Heart Disease
Condition
Acute Coronary Syndrome
Condition
Angina Pectoris
Intervention (Device)
Freesolve RMS
Intervention (Device)
Xience DES
Lead sponsor
Biotronik AG (class: industry)

Record details

Record id
cardio:ct-nct05540223
Content hash
1ab827d118c4829ab5176e6bf8ca707479b954f1d25d4e33a7150f42161c3a7c